HighGravityDataCencora — Nov 5, 2025 release
Fiscal 2025 fourth-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001140859-25-000128
Showing in the filing
Quarterly dividend
“$0.60 per common share”
Period
No period stated
Measure
Declared action
Source
Prose
All guidance in this release · 20
Planned investments to strengthen U.S. distr… for FY2030
“$1 billion”
Quarterly dividend
“$0.60 per common share”
Revenue for FY2026
“5% to 7% growth”
U.S. Healthcare Solutions Segment Revenue for FY2026
“5% to 7% growth”
International Healthcare Solutions Segment R… for FY2026
“6% to 8% growth”
Other Revenue for FY2026
“0% to 4% growth”
Other (1) for FY2026
“0% to 4% growth”
Adjusted operating income for FY2026
“8% to 10% growth”
U.S. Healthcare Solutions Segment (1) - Adju… for FY2026
“9% to 11% growth”
International Healthcare Solutions Segment (… for FY2026
“5% to 8% growth”
Other (1) - Adjusted operating income for FY2026
“1% to 4% decline”
Adjusted diluted earnings per share for FY2026
“$17.45 to $17.75”
Net interest expense for FY2026
“$315M to $335M”
Adjusted effective tax rate for FY2026
“20% to 21%”
Diluted weighted average shares outstanding for FY2026
“~194M”
Adjusted free cash flow for FY2026
“~$3.0B”
Capital expenditures for FY2026
“~$900M”
Adjusted operating income for the long term
“6% to 9%”
Capital deployment for the long term
“3% to 4%”
Adjusted diluted earnings per share for the long term
“9% to 13%”
Exhibit 99.1 · the passage around this item
… earlier in the release
The planned investments include opening a second national distribution center, expanding multiple distribution center facilities and increasing cold chain storage capacity to support the growth of specialty pharmaceuticals. Dividend Declaration On November 4, 2025, the Company’s Board of Directors declared a quarterly dividend of $0.60 per common share, a 9 percent increase in its quarterly dividend rate from $0.55 per common share. The quarterly dividend of $0.60 per common share is payable December 1, 2025, to stockholders of record at the close of business on November 14, 2025. Reportable Segments (revised as of October 1, 2025) Recently, Cencora undertook a strategic review of its business to ensure alignment with its growth priorities and strategic drivers. As a result of this review, the Company has reorganized certain business components within its reporting structure. Beginning in the first quarter of fiscal 2026, the Company's reporting structure will be comprised of U.S. Healthcare Solutions, International Healthcare Solutions, and Other. The U.S. Healthcare Solutions reportable segment will consist of U.S. Human Health (excluding legacy U.S. Consulting Services). The International Healthcare Solutions reportable segment will consist of Alliance Healthcare, Innomar, World Courier, and strategic components of PharmaLex. Other, which is not considered a reportable segment, will consist of businesses for which the Company has begun to explore strategic alternatives and includes MWI Animal Health, Profarma, U.S. Consulting
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.